Fujifilm SonoSite Inc. announced the launch of its redesigned SonoSite Institute, a comprehensive online educational resource dedicated to empowering and educating healthcare providers about point-of-care ultrasound (POCUS). Based on the feedback of current global users, the enhanced website now features an improved user experience, easier-to-locate content and reconfigured learning paths.

November 1, 2018 — Daxor Corp. has entered an agreement with CHF Solutions to explore clinical synergies between Daxor’s ...

Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (evolocumab) in patients with established cardiovascular disease by kidney function. In line with previous FOURIER subgroup analyses, these results further demonstrate Repatha's efficacy in reducing not only low-density lipoprotein cholesterol (LDL-C) levels, but also the relative risk for major cardiovascular events such as heart attack and stroke, in high-risk patients including those with mild-to-moderate chronic kidney disease (CKD).1-4 In these patients (N=4,443), absolute reductions tended to be greater in the risk for the composite secondary endpoint which included cardiovascular death, heart attack or stroke. Adverse events were similar across patients regardless of CKD stage and consistent with the Repatha known safety profile.

Blood pressure readings of 130/80 millimeters of mercury (mmHg) or higher taken at home can be used to diagnose hypertension in white, black and Hispanic U.S. adults, according to new research in the American Heart Association’s journal Hypertension.

October 29, 2018 — Good Samaritan Hospital recently became the first hospital on the West Coast to utilize the Carto ...

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low risk of experiencing a heart attack. The results are similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.